Long Term Debt Summary of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc.'s latest annual long term debt in 2023 was 1.16 Million USD , down -28.51% from previous year.
Windtree Therapeutics, Inc.'s latest quarterly long term debt in 2024 Q2 was 912 Thousand USD , down 0.0% from previous quarter.
Windtree Therapeutics, Inc. reported annual long term debt of 1.62 Million USD in 2022, down -21.58% from previous year.
Windtree Therapeutics, Inc. reported annual long term debt of 2.07 Million USD in 2021, down -21.07% from previous year.
Windtree Therapeutics, Inc. reported quarterly long term debt of 912 Thousand USD for 2024 Q2, down 0.0% from previous quarter.
Windtree Therapeutics, Inc. reported quarterly long term debt of 1.16 Million USD for 2023 FY, down -28.51% from previous quarter.

Annual Long Term Debt Chart of Windtree Therapeutics, Inc. (2023 - 1995)

Historical Annual Long Term Debt of Windtree Therapeutics, Inc. (2023 - 1995)

Year	Long Term Debt	Long Term Debt Growth
2023	1.16 Million USD	-28.51%
2022	1.62 Million USD	-21.58%
2021	2.07 Million USD	-21.07%
2020	2.62 Million USD	-51.43%
2019	5.4 Million USD	-63.99%
2018	15 Million USD	0.0%
2017	15 Million USD	-40.0%
2016	25 Million USD	0.0%
2015	25 Million USD	23.14%
2014	20.3 Million USD	10.2%
2013	18.42 Million USD	3017.26%
2012	591 Thousand USD	-35.27%
2011	913 Thousand USD	-2.35%
2010	935 Thousand USD	118.46%
2009	428 Thousand USD	-95.77%
2008	10.12 Million USD	-19.77%
2007	12.62 Million USD	8.88%
2006	11.59 Million USD	248.9%
2005	3.32 Million USD	-56.18%
2004	7.58 Million USD	966.53%
2003	711 Thousand USD	177.73%
2002	256 Thousand USD	675.76%
2001	33 Thousand USD	6.45%
2000	31 Thousand USD	-35.42%
1999	48 Thousand USD	0.0%
1998	- USD	0.0%
1997	- USD	0.0%
1996	- USD	0.0%
1995	- USD	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q1	1.03 Million USD	0.0%
2024 Q2	912 Thousand USD	0.0%
2023 FY	1.16 Million USD	-28.51%
2023 Q1	1.51 Million USD	-6.9%
2023 Q4	1.16 Million USD	-7.19%
2023 Q3	1.25 Million USD	-10.45%
2023 Q2	1.39 Million USD	-7.61%
2022 Q1	1.94 Million USD	-6.13%
2022 Q3	1.73 Million USD	-5.82%
2022 Q4	1.62 Million USD	-6.24%
2022 FY	1.62 Million USD	-21.58%
2022 Q2	1.83 Million USD	-5.4%
2021 Q2	2.31 Million USD	-4.92%
2021 FY	2.07 Million USD	-21.07%
2021 Q4	2.07 Million USD	-5.69%
2021 Q3	2.19 Million USD	-5.26%
2021 Q1	2.43 Million USD	-7.09%
2020 Q3	2.72 Million USD	437.94%
2020 Q4	2.62 Million USD	-3.6%
2020 Q2	506 Thousand USD	-90.28%
2020 FY	2.62 Million USD	-51.43%
2020 Q1	5.2 Million USD	-3.65%
2019 FY	5.4 Million USD	-63.99%
2019 Q4	5.4 Million USD	466.84%
2019 Q1	1.25 Million USD	0.0%
2019 Q3	953 Thousand USD	-10.93%
2019 Q2	1.07 Million USD	-14.47%
2018 FY	15 Million USD	0.0%
2018 Q3	- USD	0.0%
2018 Q4	- USD	0.0%
2018 Q1	- USD	0.0%
2018 Q2	- USD	0.0%
2017 Q2	12.5 Million USD	0.0%
2017 Q1	12.5 Million USD	-50.0%
2017 FY	15 Million USD	-40.0%
2017 Q4	- USD	-100.0%
2017 Q3	12.5 Million USD	0.0%
2016 Q1	25 Million USD	0.0%
2016 FY	25 Million USD	0.0%
2016 Q2	25 Million USD	0.0%
2016 Q4	25 Million USD	0.0%
2016 Q3	25 Million USD	0.0%
2015 Q1	20.85 Million USD	2.73%
2015 FY	25 Million USD	23.14%
2015 Q2	21.45 Million USD	2.85%
2015 Q4	25 Million USD	0.0%
2015 Q3	25 Million USD	16.54%
2014 FY	20.3 Million USD	10.2%
2014 Q3	19.77 Million USD	2.5%
2014 Q4	20.3 Million USD	2.66%
2014 Q2	19.29 Million USD	2.39%
2014 Q1	18.84 Million USD	2.27%
2013 Q1	6.21 Million USD	951.1%
2013 Q4	18.42 Million USD	187.19%
2013 Q3	6.41 Million USD	1.66%
2013 Q2	6.31 Million USD	1.58%
2013 FY	18.42 Million USD	3017.26%
2012 Q2	872 Thousand USD	-3.96%
2012 FY	591 Thousand USD	-35.27%
2012 Q4	591 Thousand USD	-29.39%
2012 Q3	837 Thousand USD	-4.01%
2012 Q1	908 Thousand USD	305.36%
2011 FY	913 Thousand USD	-2.35%
2011 Q4	224 Thousand USD	-75.99%
2011 Q3	933 Thousand USD	-3.62%
2011 Q2	968 Thousand USD	-2.32%
2011 Q1	991 Thousand USD	229.24%
2010 Q1	1.07 Million USD	151.87%
2010 Q4	301 Thousand USD	-8.23%
2010 Q2	1.02 Million USD	-5.19%
2010 Q3	328 Thousand USD	-67.91%
2010 FY	935 Thousand USD	118.46%
2009 FY	428 Thousand USD	-95.77%
2009 Q1	11.1 Million USD	-1.01%
2009 Q2	714 Thousand USD	-93.57%
2009 Q3	1.24 Million USD	73.95%
2009 Q4	428 Thousand USD	-65.54%
2008 Q1	12.16 Million USD	-3.64%
2008 Q2	9.9 Million USD	-18.59%
2008 FY	10.12 Million USD	-19.77%
2008 Q3	11.36 Million USD	14.73%
2008 Q4	11.22 Million USD	-1.25%
2007 Q4	12.62 Million USD	3.31%
2007 Q1	11.32 Million USD	-2.33%
2007 Q2	11.75 Million USD	3.81%
2007 FY	12.62 Million USD	8.88%
2007 Q3	12.22 Million USD	3.96%
2006 Q3	2.86 Million USD	-12.64%
2006 FY	11.59 Million USD	248.9%
2006 Q1	3.04 Million USD	-8.43%
2006 Q2	3.28 Million USD	7.85%
2006 Q4	11.59 Million USD	304.39%
2005 Q3	10.08 Million USD	0.04%
2005 Q4	3.32 Million USD	-67.06%
2005 Q2	10.08 Million USD	-0.45%
2005 Q1	10.12 Million USD	33.58%
2005 FY	3.32 Million USD	-56.18%
2004 FY	7.58 Million USD	966.53%
2004 Q4	7.58 Million USD	468.44%
2004 Q3	1.33 Million USD	12.38%
2004 Q2	1.18 Million USD	42.5%
2004 Q1	833 Thousand USD	17.16%
2003 Q3	485 Thousand USD	67.24%
2003 Q2	290 Thousand USD	-16.67%
2003 Q4	711 Thousand USD	46.6%
2003 FY	711 Thousand USD	177.73%
2003 Q1	348 Thousand USD	35.94%
2002 Q4	256 Thousand USD	-80.69%
2002 FY	256 Thousand USD	675.76%
2002 Q2	9000.00 USD	-57.14%
2002 Q1	21 Thousand USD	-36.36%
2002 Q3	1.32 Million USD	14633.33%
2001 Q2	21 Thousand USD	-12.5%
2001 Q1	24 Thousand USD	-22.58%
2001 Q3	17 Thousand USD	-19.05%
2001 Q4	33 Thousand USD	94.12%
2001 FY	33 Thousand USD	6.45%
2000 Q2	40 Thousand USD	-9.09%
2000 Q1	44 Thousand USD	-8.33%
2000 Q4	31 Thousand USD	-13.89%
2000 Q3	36 Thousand USD	-10.0%
2000 FY	31 Thousand USD	-35.42%
1999 FY	48 Thousand USD	0.0%
1999 Q1	- USD	0.0%
1999 Q2	- USD	0.0%
1999 Q3	- USD	0.0%
1999 Q4	48 Thousand USD	0.0%
1998 FY	- USD	0.0%
1998 Q4	- USD	0.0%
1998 Q3	- USD	0.0%
1998 Q2	- USD	0.0%
1998 Q1	- USD	0.0%
1997 Q2	- USD	-100.0%
1997 FY	- USD	0.0%
1997 Q4	- USD	0.0%
1997 Q3	- USD	0.0%
1997 Q1	1 Million USD	0.0%
1996 Q4	- USD	0.0%
1996 Q1	- USD	0.0%
1996 Q3	- USD	0.0%
1996 FY	- USD	0.0%
1996 Q2	- USD	0.0%
1995 FY	- USD	0.0%
1995 Q4	- USD	0.0%
1995 Q2	1.1 Million USD	0.0%
1995 Q1	- USD	0.0%

Peer Long Term Debt Comparison of Windtree Therapeutics, Inc.

Name	Long Term Debt	Long Term Debt Difference
Burzynski Research Institute, Inc.	- USD	-Infinity%
Arch Therapeutics, Inc.	- USD	-Infinity%
Evofem Biosciences, Inc.	8000.00 USD	-14412.5%
Nascent Biotech, Inc.	- USD	-Infinity%
Rebus Holdings, Inc.	- USD	-Infinity%
Santhera Pharmaceuticals Holding AG	1.75 Million USD	33.864%
Qrons Inc.	80 Thousand USD	-1351.25%
Adynxx, Inc.	- USD	-Infinity%
Neon Bloom, Inc.	- USD	-Infinity%
Northwest Biotherapeutics, Inc.	20.31 Million USD	94.284%
ProtoKinetix, Incorporated	- USD	-Infinity%
Skye Bioscience, Inc.	171.23 Thousand USD	-578.035%
Eiger BioPharmaceuticals, Inc.	- USD	-Infinity%
Nanobac Pharmaceuticals, Incorporated	- USD	-Infinity%
Institute of Biomedical Research Corp.	- USD	-Infinity%
SQZ Biotechnologies Company	20.9 Million USD	94.447%
Intellipharmaceutics International Inc.	- USD	-Infinity%
Propanc Biopharma, Inc.	58.64 Thousand USD	-1879.81%
Mesoblast Limited	100.29 Million USD	98.842%
Marizyme, Inc.	667.12 Thousand USD	-74.029%
Genus plc	228.2 Million USD	99.491%
VioQuest Pharmaceuticals, Inc.	- USD	-Infinity%
Pharming Group N.V.	166.1 Million USD	99.301%
Therapeutic Solutions International, Inc.	5512.00 USD	-20963.135%
CNBX Pharmaceuticals Inc.	- USD	-Infinity%
Nymox Pharmaceutical Corporation	- USD	-Infinity%
ContraFect Corporation	2.21 Million USD	47.466%
PsyBio Therapeutics Corp.	- USD	-Infinity%
Sienna Biopharmaceuticals, Inc.	- USD	-Infinity%
RegeneRx Biopharmaceuticals, Inc.	1.4 Million USD	17.245%
IMV Inc.	27.39 Million USD	95.763%
AXIM Biotechnologies, Inc.	5.42 Million USD	78.605%
MultiCell Technologies, Inc.	36.43 USD	-3186833.846%
ONE Bio Corp.	592.19 Thousand USD	-96.049%
Accustem Sciences Inc.	- USD	-Infinity%
RVL Pharmaceuticals plc	55.61 Million USD	97.912%
Arno Therapeutics, Inc.	- USD	-Infinity%
EV Biologics, Inc.	- USD	-Infinity%
Q BioMed Inc.	- USD	-Infinity%
Emmaus Life Sciences, Inc.	2.22 Million USD	47.844%
Mosaic ImmunoEngineering Inc.	1.22 Million USD	5.484%
Biomind Labs Inc.	- USD	-Infinity%
American Oriental Bioengineering, Inc.	554.59 Thousand USD	-109.344%
Provectus Biopharmaceuticals, Inc.	25.29 Thousand USD	-4489.114%
TetraLogic Pharmaceuticals Corporation	- USD	-Infinity%
Oncotelic Therapeutics, Inc.	1.89 Million USD	38.845%
GlobeStar Therapeutics Corporation	- USD	-Infinity%
THC Farmaceuticals, Inc.	- USD	-Infinity%
Acro Biomedical Co., Ltd.	- USD	-Infinity%
Curative Biotechnology, Inc.	- USD	-Infinity%
GB Sciences, Inc.	322 Thousand USD	-260.559%
Alpha Cognition Inc.	- USD	-Infinity%
HST Global, Inc.	- USD	-Infinity%
CSL Limited	11.23 Billion USD	99.99%
Wesana Health Holdings Inc.	- USD	-Infinity%
Halberd Corporation	150 Thousand USD	-674.0%
Enzolytics Inc.	- USD	-Infinity%
Agentix Corp.	- USD	-Infinity%
Resverlogix Corp.	- USD	-Infinity%
Nuo Therapeutics, Inc.	164.2 Thousand USD	-607.043%
MetaStat, Inc.	- USD	-Infinity%
argenx SE	15.35 Million USD	92.438%
Enzon Pharmaceuticals, Inc.	- USD	-Infinity%
Endonovo Therapeutics, Inc.	- USD	-Infinity%
RespireRx Pharmaceuticals Inc.	- USD	-Infinity%
GeneThera, Inc.	- USD	-Infinity%
Inhibitor Therapeutics, Inc.	- USD	-Infinity%
AVAX Technologies, Inc.	- USD	-Infinity%
Zenith Capital Corp.	4456.00 USD	-25954.758%
Genscript Biotech Corporation	287.12 Million USD	99.596%
Ember Therapeutics, Inc.	- USD	-Infinity%
Anthera Pharmaceuticals, Inc.	- USD	-Infinity%
Sigyn Therapeutics, Inc.	126.3 Thousand USD	-819.225%
WPD Pharmaceuticals Inc.	229.29 Thousand USD	-406.343%
Cotinga Pharmaceuticals Inc.	- USD	-Infinity%
Kadimastem Ltd	229.69 Thousand USD	-405.462%
Helix BioMedix, Inc.	- USD	-Infinity%
VitaSpring Biomedical Co. Ltd.	- USD	-Infinity%
Capstone Therapeutics Corp.	8.26 Million USD	85.951%
BioStem Technologies, Inc.	265.63 Thousand USD	-337.066%
Oncology Pharma Inc.	- USD	-Infinity%
Reve Technologies, Inc.	1064.00 USD	-109016.541%
LadRx Corporation	- USD	-Infinity%
Cell Source, Inc.	- USD	-Infinity%
Regen BioPharma, Inc.	149.61 Thousand USD	-675.997%
Regen BioPharma, Inc.	149.61 Thousand USD	-675.997%
NovAccess Global Inc.	- USD	-Infinity%
Affymax, Inc.	- USD	-Infinity%
Itoco Inc.	- USD	-Infinity%
Rasna Therapeutics, Inc.	- USD	-Infinity%
Pathfinder Cell Therapy, Inc.	- USD	-Infinity%
Mobile Lads Corp.	- USD	-Infinity%
CytoDyn Inc.	141 Thousand USD	-723.404%
Claritas Pharmaceuticals, Inc.	- USD	-Infinity%
NDT Pharmaceuticals Inc.	- USD	-Infinity%
NanoSphere Health Sciences Inc.	- USD	-Infinity%
Alseres Pharmaceuticals, Inc.	7.81 Million USD	85.153%
SYBLEU INC	300 Thousand USD	-287.0%
Advanced Proteome Therapeutics Corporation	- USD	-Infinity%
ImmunoCellular Therapeutics, Ltd.	369.04 Thousand USD	-214.592%
International Stem Cell Corporation	445 Thousand USD	-160.899%
Bioxytran, Inc.	- USD	-Infinity%
GlobeImmune, Inc.	- USD	-Infinity%
Predictive Technology Group, Inc.	- USD	-Infinity%
ProText Mobility, Inc.	- USD	-Infinity%
Cardax, Inc.	- USD	-Infinity%
VG Life Sciences Inc.	- USD	-Infinity%
Kaleido Biosciences, Inc.	- USD	-Infinity%
Advaxis, Inc.	8.15 Million USD	85.755%
Adhera Therapeutics, Inc.	- USD	-Infinity%
RenovaCare, Inc.	- USD	-Infinity%
Regnum Corp.	- USD	-Infinity%
Innovation Pharmaceuticals Inc.	457 Thousand USD	-154.048%
Neutra Corp.	- USD	-Infinity%
PureTech Health plc	18.25 Million USD	93.638%
Coeptis Therapeutics, Inc.	150 Thousand USD	-674.0%
IXICO plc	275 Thousand USD	-322.182%
IntelGenx Technologies Corp.	11.83 Million USD	90.193%
Gelesis Holdings, Inc.	26.3 Million USD	95.587%
CSL Limited	11.23 Billion USD	99.99%
Cellectis S.A.	36.21 Million USD	96.794%

Global Stocks Search

Windtree Therapeutics, Inc. (WINTW)

Long Term Debt Summary of Windtree Therapeutics, Inc.

Annual Long Term Debt Chart of Windtree Therapeutics, Inc. (2023 - 1995)

Historical Annual Long Term Debt of Windtree Therapeutics, Inc. (2023 - 1995)

Peer Long Term Debt Comparison of Windtree Therapeutics, Inc.